Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed

• Sponsor: NCIC Clinical Trials Group (Other)
• Overall Status: Completed
• CT.gov ID: NCT00002583
• Collaborator: National Cancer Institute (NCI) (NIH), Southwest Oncology Group (Other), Eastern Cooperative Oncology Group (Other), Cancer and Leukemia Group B (Other)
• Enrollment: 482
• Locations: 155
• Arms: 2
• Actual Duration (Months): 185.5
• Patients Per Site: 3.1
• Patients Per Site Per Month: 0

Study Details

Study Description

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy is more effective than no further treatment for non-small cell lung cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of vinorelbine plus cisplatin with that of no further therapy in treating patients who have stage I or stage II non-small cell lung cancer that has been completely removed during surgery.

Condition or Disease	Intervention/Treatment	Phase
Lung Cancer	Drug: cisplatin; Drug: vinorelbine ditartrate	Phase 3

Detailed Description

OBJECTIVES: I. Compare the duration of overall and disease-free survival in patients with completely resected non-small cell lung cancer (NSCLC) randomized to adjuvant chemotherapy with vinorelbine and cisplatin versus observation only. II. Confirm the prognostic significance of ras mutations when present in the primary tumor. III. Provide a comprehensive tumor bank linked to a clinical database for the further study of molecular markers in resected NSCLC. IV. Measure and compare the health-related quality of life of patients on both treatment arms. V. Evaluate any toxicity related to this treatment regimen.

OUTLINE: This is a randomized study. Patients are stratified according to participating institution, nodal status (N0 vs N1), and ras mutation status of primary tumor (absent vs present vs unknown). Patients are randomized to one of two treatment arms. Arm I: Patients are evaluated at 3 and 6 months after randomization. Arm II: Patients receive vinorelbine IV over 6-10 minutes weekly for 16 weeks. Patients also receive cisplatin IV on days 1 and 8 every 4 weeks for a total of 4 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at Canadian centers. Quality of life assessments are optional for ECOG and SWOG centers. Patients are followed every 3 months for 2 years and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 450 patients will be accrued for this study within 6.75 years.

Study Design

• Study Type: Interventional
• Actual Enrollment: 482 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase III Prospective Randomized Study of Adjuvant Chemotherapy With Vinorelbine and Cisplatin in Completely Resected Non-Small Cell Lung Cancer With Companion Tumour Marker Evaluation
• Actual Study Start Date: Jul 7, 1994
• Actual Primary Completion Date: Apr 25, 2004
• Actual Study Completion Date: Dec 21, 2009

Arms and Interventions

Arm	Intervention/Treatment
No Intervention: Observation Observation only
Active Comparator: Chemotherapy Cisplatin and Vinorelbine	Drug: cisplatin; 50 mg/m2 IV; Drug: vinorelbine ditartrate; 25 mg/m2 IV

Outcome Measures

Primary Outcome Measures

1. survival [At time of death]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 120 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

DISEASE CHARACTERISTICS: Histologically confirmed primary non-small cell lung cancer that is completely resected No mixed small and non-small cell histologies Pathologic T2 N0 or T1-2 N1 T1 N1 and T2 N1 only for CALGB institutions Removal of all gross disease with negative resection margins by lobectomy, sleeve resection, bilobectomy, or pneumonectomy (based on intraoperative findings) No segmentectomy or wedge resection Complete mediastinal lymph node resection or sampling required at primary tumor resection, with minimum levels of nodal sampling as follows: Primary in right upper lobe - levels 4, 7, 10 Primary in right middle lobe - levels 4, 7, 10 Primary in right lower lobe - levels 4, 7, 9, 10 Primary in left upper lobe - levels 5, 6, 7, 10 Primary in left lower lobe - levels 7, 9, 10 If complete mediastinal lymph node resection has not been undertaken, any mediastinal lymph node which measured 1.5 cm or more on presurgical CT scan must have been biopsied and found to be free of metastatic involvement Disease at nodal station 10 (tracheobronchial angle) is considered N2 disease for this trial and is not eligible No more than one discrete primary tumor No bronchoalveolar carcinoma with lobar or multilobar involvement Discrete solitary radiological mass or nodule eligible Snap frozen fresh primary tumor tissue must be submitted to Lung Cancer Tumor Bank within 14 days after surgery by selected Canadian centers Others to submit representative paraffin block within 2 months of surgery

PATIENT CHARACTERISTICS: Age: 18 and over (lower age limit determined by individual center) Performance status: ECOG 0 or 1 Life expectancy: Not specified Hematopoietic: Absolute granulocyte count greater than 2,000/mm3 Platelet count greater than 100,000/mm3 Hemoglobin greater than 10.0 g/dL Hepatic: Bilirubin no greater than 1.25 times normal AST/ALT no greater than 1.25 times normal Alkaline phosphatase no greater than 1.25 times normal Renal: Creatinine no greater than 1.7 mg/dL Cardiovascular: No history of congestive heart failure or other cardiac abnormality that may preclude hydration necessary for cisplatin administration Other: No active pathologic condition that would preclude study No active uncontrolled infection No history of psychiatric or neurologic disorder that would preclude study No prior breast cancer, melanoma, or hypernephroma No other malignancy within the past 5 years except adequately treated nonmelanomatous skin cancer or carcinoma in situ of the cervix Not pregnant or nursing Fertile patients must use effective contraception Ability to tolerate treatment (based on consultation between the thoracic surgeon and a medical oncologist or hematologist) and available for follow-up

PRIOR CONCURRENT THERAPY: Complete resection required Randomization between 28 and 40 days after surgery required

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Veterans Affairs Medical Center - Birmingham	Birmingham	Alabama	United States	35233
2	MBCCOP - University of South Alabama	Mobile	Alabama	United States	36688
3	CCOP - Greater Phoenix	Phoenix	Arizona	United States	85006-2726
4	Veterans Affairs Medical Center - Phoenix (Hayden)	Phoenix	Arizona	United States	85012
5	Veterans Affairs Medical Center - Tucson	Tucson	Arizona	United States	85723
6	Arizona Cancer Center	Tucson	Arizona	United States	85724
7	University of Arkansas for Medical Sciences	Little Rock	Arkansas	United States	72205
8	Veterans Affairs Medical Center - Little Rock (McClellan)	Little Rock	Arkansas	United States	72205
9	University of California San Diego Cancer Center	La Jolla	California	United States	92093-0658
10	Veterans Affairs Medical Center - Long Beach	Long Beach	California	United States	90822
11	USC/Norris Comprehensive Cancer Center	Los Angeles	California	United States	90033-0800
12	Jonsson Comprehensive Cancer Center, UCLA	Los Angeles	California	United States	90095-1781
13	Beckman Research Institute, City of Hope	Los Angeles	California	United States	91010
14	Veterans Affairs Outpatient Clinic - Martinez	Martinez	California	United States	94553
15	CCOP - Bay Area Tumor Institute	Oakland	California	United States	94609-3305
16	Chao Family Comprehensive Cancer Center	Orange	California	United States	92868
17	University of California Davis Medical Center	Sacramento	California	United States	95817
18	UCSF Cancer Center and Cancer Research Institute	San Francisco	California	United States	94115-0128
19	CCOP - Santa Rosa Memorial Hospital	Santa Rosa	California	United States	95403
20	David Grant Medical Center	Travis Air Force Base	California	United States	94535
21	Veterans Affairs Medical Center - Denver	Denver	Colorado	United States	80220
22	University of Colorado Cancer Center	Denver	Colorado	United States	80262
23	CCOP - Christiana Care Health Services	Wilmington	Delaware	United States	19899
24	Walter Reed Army Medical Center	Washington	District of Columbia	United States	20307-5000
25	CCOP - Mount Sinai Medical Center	Miami Beach	Florida	United States	33140
26	CCOP - Atlanta Regional	Atlanta	Georgia	United States	30342-1701
27	Dwight David Eisenhower Army Medical Center	Fort Gordon	Georgia	United States	30905-5650
28	Cancer Research Center of Hawaii	Honolulu	Hawaii	United States	96813
29	University of Illinois at Chicago Health Sciences Center	Chicago	Illinois	United States	60612
30	University of Chicago Cancer Research Center	Chicago	Illinois	United States	60637
31	CCOP - Central Illinois	Decatur	Illinois	United States	62526
32	Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)	Hines	Illinois	United States	60141
33	Loyola University Medical Center	Maywood	Illinois	United States	60153
34	University of Iowa Hospitals and Clinics	Iowa City	Iowa	United States	52242
35	University of Kansas Medical Center	Kansas City	Kansas	United States	66160-7357
36	CCOP - Wichita	Wichita	Kansas	United States	67214-3882
37	Veterans Affairs Medical Center - Wichita	Wichita	Kansas	United States	67218
38	Veterans Affairs Medical Center - Lexington	Lexington	Kentucky	United States	40511-1093
39	Albert B. Chandler Medical Center, University of Kentucky	Lexington	Kentucky	United States	40536-0084
40	MBCCOP - LSU Medical Center	New Orleans	Louisiana	United States	70112
41	Tulane University School of Medicine	New Orleans	Louisiana	United States	70112
42	Veterans Affairs Medical Center - New Orleans	New Orleans	Louisiana	United States	70112
43	Louisiana State University Health Sciences Center - Shreveport	Shreveport	Louisiana	United States	71130-3932
44	Veterans Affairs Medical Center - Shreveport	Shreveport	Louisiana	United States	71130
45	Veterans Affairs Medical Center - Togus	Togus	Maine	United States	04330
46	Marlene & Stewart Greenebaum Cancer Center, University of Maryland	Baltimore	Maryland	United States	21201
47	Dana-Farber Cancer Institute	Boston	Massachusetts	United States	02115
48	Boston Medical Center	Boston	Massachusetts	United States	02118
49	Veterans Affairs Medical Center - Boston (Jamaica Plain)	Jamaica Plain	Massachusetts	United States	02130
50	University of Massachusetts Memorial Medical Center	Worcester	Massachusetts	United States	01655
51	Veterans Affairs Medical Center - Ann Arbor	Ann Arbor	Michigan	United States	48105
52	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan	United States	48109-0752
53	Veterans Affairs Medical Center - Detroit	Detroit	Michigan	United States	48201-1932
54	Barbara Ann Karmanos Cancer Institute	Detroit	Michigan	United States	48201
55	Henry Ford Hospital	Detroit	Michigan	United States	48202
56	CCOP - Grand Rapids Clinical Oncology Program	Grand Rapids	Michigan	United States	49503
57	Providence Hospital - Southfield	Southfield	Michigan	United States	48075-9975
58	Veterans Affairs Medical Center - Minneapolis	Minneapolis	Minnesota	United States	55417
59	University of Minnesota Cancer Center	Minneapolis	Minnesota	United States	55455
60	Veterans Affairs Medical Center - Biloxi	Biloxi	Mississippi	United States	39531-2410
61	University of Mississippi Medical Center	Jackson	Mississippi	United States	39216-4505
62	Veterans Affairs Medical Center - Jackson	Jackson	Mississippi	United States	39216
63	Keesler Medical Center - Keesler AFB	Keesler Air Force Base	Mississippi	United States	39534-2576
64	Veterans Affairs Medical Center - Columbia (Truman Memorial)	Columbia	Missouri	United States	65201
65	Ellis Fischel Cancer Center - Columbia	Columbia	Missouri	United States	65203
66	University of Missouri	Columbia	Missouri	United States	65212
67	Veterans Affairs Medical Center - Kansas City	Kansas City	Missouri	United States	64128
68	CCOP - Kansas City	Kansas City	Missouri	United States	64131
69	St. Louis University Health Sciences Center	Saint Louis	Missouri	United States	63110-0250
70	Barnes-Jewish Hospital	Saint Louis	Missouri	United States	63110
71	CCOP - St. Louis-Cape Girardeau	Saint Louis	Missouri	United States	63141
72	CCOP - Cancer Research for the Ozarks	Springfield	Missouri	United States	65807
73	CCOP - Montana Cancer Consortium	Billings	Montana	United States	59101
74	University of Nebraska Medical Center	Omaha	Nebraska	United States	68198-3330
75	CCOP - Southern Nevada Cancer Research Foundation	Las Vegas	Nevada	United States	89106
76	Norris Cotton Cancer Center	Lebanon	New Hampshire	United States	03756
77	Hunterdon Regional Cancer Center	Flemington	New Jersey	United States	08822
78	Hackensack University Medical Center	Hackensack	New Jersey	United States	07601
79	St. Barnabas Medical Center	Livingston	New Jersey	United States	07039
80	Morristown Memorial Hospital	Morristown	New Jersey	United States	07962-1956
81	Riverview Medical Center	Red Bank	New Jersey	United States	07701
82	St. Francis Medical Center	Trenton	New Jersey	United States	08629
83	Veterans Affairs Medical Center - Albuquerque	Albuquerque	New Mexico	United States	87108-5138
84	MBCCOP - University of New Mexico HSC	Albuquerque	New Mexico	United States	87131
85	Veterans Affairs Medical Center - Buffalo	Buffalo	New York	United States	14215
86	Roswell Park Cancer Institute	Buffalo	New York	United States	14263-0001
87	CCOP - North Shore University Hospital	Manhasset	New York	United States	11030
88	North Shore University Hospital	Manhasset	New York	United States	11030
89	Memorial Sloan-Kettering Cancer Center	New York	New York	United States	10021
90	New York Presbyterian Hospital - Cornell Campus	New York	New York	United States	10021
91	Mount Sinai Medical Center, NY	New York	New York	United States	10029
92	Herbert Irving Comprehensive Cancer Center	New York	New York	United States	10032
93	State University of New York - Upstate Medical University	Syracuse	New York	United States	13210
94	Veterans Affairs Medical Center - Syracuse	Syracuse	New York	United States	13210
95	CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.	Syracuse	New York	United States	13217
96	Lineberger Comprehensive Cancer Center, UNC	Chapel Hill	North Carolina	United States	27599-7295
97	Veterans Affairs Medical Center - Durham	Durham	North Carolina	United States	27705
98	Duke Comprehensive Cancer Center	Durham	North Carolina	United States	27710
99	CCOP - Southeast Cancer Control Consortium	Winston-Salem	North Carolina	United States	27104-4241
100	Comprehensive Cancer Center of Wake Forest University Baptist Medical Center	Winston-Salem	North Carolina	United States	27157-1082
101	Barrett Cancer Center, The University Hospital	Cincinnati	Ohio	United States	45219
102	Veterans Affairs Medical Center - Cincinnati	Cincinnati	Ohio	United States	45220-2288
103	Cleveland Clinic Taussig Cancer Center	Cleveland	Ohio	United States	44195
104	CCOP - Columbus	Columbus	Ohio	United States	43206
105	Veterans Affairs Medical Center - Dayton	Dayton	Ohio	United States	45428
106	CCOP - Dayton	Kettering	Ohio	United States	45429
107	Oklahoma Medical Research Foundation	Oklahoma City	Oklahoma	United States	73104
108	Veterans Affairs Medical Center - Oklahoma City	Oklahoma City	Oklahoma	United States	73104
109	Oregon Cancer Center at Oregon Health Sciences University	Portland	Oregon	United States	97201-3098
110	Veterans Affairs Medical Center - Portland	Portland	Oregon	United States	97207
111	CCOP - Columbia River Program	Portland	Oregon	United States	97213
112	Rhode Island Hospital	Providence	Rhode Island	United States	02903
113	Medical University of South Carolina	Charleston	South Carolina	United States	29425-0721
114	CCOP - Greenville	Greenville	South Carolina	United States	29615
115	CCOP - Upstate Carolina	Spartanburg	South Carolina	United States	29303
116	University of Tennessee, Memphis Cancer Center	Memphis	Tennessee	United States	38103
117	Veterans Affairs Medical Center - Memphis	Memphis	Tennessee	United States	38104
118	Simmons Cancer Center - Dallas	Dallas	Texas	United States	75235-9154
119	Brooke Army Medical Center	Fort Sam Houston	Texas	United States	78234
120	University of Texas Medical Branch	Galveston	Texas	United States	77555-0209
121	Texas Tech University Health Science Center	Lubbock	Texas	United States	79423
122	University of Texas Health Science Center at San Antonio	San Antonio	Texas	United States	78284-7811
123	Veterans Affairs Medical Center - San Antonio (Murphy)	San Antonio	Texas	United States	78284
124	Veterans Affairs Medical Center - Temple	Temple	Texas	United States	76504
125	CCOP - Scott and White Hospital	Temple	Texas	United States	76508
126	Huntsman Cancer Institute	Salt Lake City	Utah	United States	84132
127	Veterans Affairs Medical Center - Salt Lake City	Salt Lake City	Utah	United States	84148
128	Veterans Affairs Medical Center - White River Junction	White River Junction	Vermont	United States	05009
129	Veterans Affairs Medical Center - Richmond	Richmond	Virginia	United States	23249
130	MBCCOP - Massey Cancer Center	Richmond	Virginia	United States	23298-0037
131	CCOP - Virginia Mason Research Center	Seattle	Washington	United States	98101
132	Swedish Cancer Institute	Seattle	Washington	United States	98104
133	Veterans Affairs Medical Center - Seattle	Seattle	Washington	United States	98108
134	University of Washington Medical Center	Seattle	Washington	United States	98195-6043
135	CCOP - Northwest	Tacoma	Washington	United States	98405-0986
136	Tom Baker Cancer Center - Calgary	Calgary	Alberta	Canada	T2N 4N2
137	Cross Cancer Institute	Edmonton	Alberta	Canada	T6G 1Z2
138	University of Alberta Hospital	Edmonton	Alberta	Canada	T6G 2B7
139	BC Cancer Agency	Vancouver	British Columbia	Canada	V5Z 4E6
140	St. Paul's Hospital - Vancouver	Vancouver	British Columbia	Canada	V6Z 1Y6
141	British Columbia Cancer Agency - Vancouver Island Cancer Centre	Victoria	British Columbia	Canada	V8R 1J8
142	CancerCare Manitoba	Winnipeg	Manitoba	Canada	R3E 0V9
143	Doctor Leon Richard Oncology Centre	Moncton	New Brunswick	Canada	E1C 8X3
144	Nova Scotia Cancer Centre	Halifax	Nova Scotia	Canada	B3H 1V7
145	Cancer Care Ontario-London Regional Cancer Centre	London	Ontario	Canada	N6A 4L6
146	Ottawa Regional Cancer Centre - General Campus	Ottawa	Ontario	Canada	K1H 1C4
147	Hotel Dieu Hospital - St. Catharines	St. Catharines	Ontario	Canada	L2R 5K3
148	Northeastern Ontario Regional Cancer Centre, Sudbury	Sudbury	Ontario	Canada	P3E 5J1
149	Northwestern Ontario Regional Cancer Centre, Thunder Bay	Thunder Bay	Ontario	Canada	P7A 7T1
150	Toronto Sunnybrook Regional Cancer Centre	Toronto	Ontario	Canada	M4N 3M5
151	Mount Sinai Hospital - Toronto	Toronto	Ontario	Canada	M5G 1X5
152	Saint Joseph's Health Centre - Toronto	Toronto	Ontario	Canada	M6R 1B5
153	Centre Hospitalier de l'Universite de Montreal	Montreal	Quebec	Canada	H2L-4M1
154	McGill University Department of Oncology	Montreal	Quebec	Canada	H2W 1S6
155	L'Hopital Laval	Ste-Foy	Quebec	Canada	G1V 4G5

Sponsors and Collaborators

• NCIC Clinical Trials Group
• National Cancer Institute (NCI)
• Southwest Oncology Group
• Eastern Cooperative Oncology Group
• Cancer and Leukemia Group B

Investigators

• Study Chair: Timothy L. Winton, MD, University of Alberta
• Study Chair: Eric Vallieres, MD, FRCSC, University of Washington
• Study Chair: Russell F. DeVore, MD, Vanderbilt-Ingram Cancer Center
• Study Chair: James R. Rigas, MD, Norris Cotton Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Publications

• Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham BC, Goss GD; National Cancer Institute of Canada Clinical Trials Group. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008 Jan 1;26(1):54-9. doi: 10.1200/JCO.2007.12.8322.
• Hicks LK, Cheung MC, Ding K, Hasan B, Seymour L, Le Maître A, Leighl NB, Shepherd FA. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer. 2009 Dec 1;115(23):5516-25. doi: 10.1002/cncr.24596.
• Hotta K, Matsuo K, Kiura K, Ueoka H, Tanimoto M. Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer. Curr Opin Oncol. 2006 Mar;18(2):144-50. Review.
• Kassam F, Shepherd FA, Johnston M, Visbal A, Feld R, Darling G, Keshavjee S, Pierre A, Waddell T, Leighl NB. Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. J Thorac Oncol. 2007 Jan;2(1):39-43.
• Ng R, Hasan B, Mittmann N, Florescu M, Shepherd FA, Ding K, Butts CA, Cormier Y, Darling G, Goss GD, Inculet R, Seymour L, Winton TL, Evans WK, Leighl NB; Working Group on Economic Analysis; Lung Disease Site Group; National Cancer Institute of Canada Clinical Trials Group. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 Jun 1;25(16):2256-61.
• Pignon JP, Tribodet H, Scagliotti GV, et al.: Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. [Abstract] J Clin Oncol 24 (Suppl 18): A-7008, 2006.
• Visbal AL, Leighl NB, Feld R, Shepherd FA. Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. Chest. 2005 Oct;128(4):2933-43. Review.
• Wakelee HA, Schiller JH, Gandara DR. Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial. Clin Lung Cancer. 2006 Jul;8(1):18-21. Review.
• Wheatley-Price P, Le Maître A, Ding K, Leighl N, Hirsh V, Seymour L, Bezjak A, Shepherd FA; NCIC Clinical Trials Group. The influence of sex on efficacy, adverse events, quality of life, and delivery of treatment in National Cancer Institute of Canada Clinical Trials Group non-small cell lung cancer chemotherapy trials. J Thorac Oncol. 2010 May;5(5):640-8. doi: 10.1097/JTO.0b013e3181d40a1b.

• Responsible Party: NCIC Clinical Trials Group
• ClinicalTrials.gov Identifier: NCT00002583
• Other Study ID Numbers: BR10; CAN-NCIC-BR10; CLB-9795; E-JBR10; SWOG-JBR10; GW-565/040; NCI-V94-0492; CDR0000063698
• First Posted: Apr 22, 2004
• Last Update Posted: Apr 3, 2020
• Last Verified: Apr 1, 2020

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Keywords provided by NCIC Clinical Trials Group: stage I non-small cell lung cancer; stage II non-small cell lung cancer
• Additional relevant MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Vinorelbine

Study Results

No Results Posted as of Apr 3, 2020